IP Library › Granted Patent US 8,211,431
Granted Patent B2
US 8,211,431 · App. 12/227,029 · Granted Jul 3, 2012

Human binding molecules having killing activity against staphylococci and uses thereof

Assignee: Crucell Holland B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,211,431
App. No.
12/227,029
Granted
Jul 3, 2012
Kind
B2
Abstract

The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Staphylococcus.

Claims (21)

1. An isolated human monoclonal antibody that has opsonic phagocytic killing activity against at least two different Staphylococcus species and against at least 3 different strains of Staphylococcus aureus , wherein the monoclonal antibody is selected from the group consisting of:

i) a human monoclonal antibody with a heavy chain comprising SEQ ID NO: 30 and a light chain comprising SEQ ID NO: 36;

ii) a human monoclonal antibody with a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 177;

iii) a human monoclonal antibody with a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 179;

iv) a human monoclonal antibody with a heavy chain comprising SEQ ID NO: 121 and a light chain comprising SEQ ID NO: 181; and

v) a human monoclonal antibody with a heavy chain comprising SEQ ID NO: 155 and a light chain comprising SEQ ID NO: 215.

2. The isolated human monoclonal antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO: 30 and the light chain comprises SEQ ID NO: 36.

3. The isolated human monoclonal antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO: 117 and the light chain comprises SEQ ID NO: 177.

4. The isolated human monoclonal antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO: 119 and the light chain comprises SEQ ID NO: 179.

5. The isolated human monoclonal antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO: 121 and the light chain comprises SEQ ID NO: 181.

6. The isolated human monoclonal antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO: 155 and the light chain comprises SEQ ID NO: 215.

7. A composition comprising at least two human monoclonal antibodies of claim 1 .

8. An immunoconjugate comprising the human monoclonal antibody of claim 1 , the immunoconjugate further comprising at least one tag.

9. A pharmaceutical composition comprising the human monoclonal antibody of claim 1 , the pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.

10. The pharmaceutical composition according to claim 9 further comprising at least one other therapeutic agent.

11. A method of diagnosing a staphylococcal infection in a subject, the method comprising:

utilizing the human monoclonal antibody of claim 1 in the diagnosis of the staphylococcal infection.

12. A method of producing the human monoclonal antibody of claim 1 , the method comprising:

culturing a host cell comprising a vector, said vector comprising a nucleic acid molecule encoding said human monoclonal antibody under conditions conducive to the expression of the human monoclonal antibody,

expressing the human monoclonal antibody, and

recovering the expressed human monoclonal antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2008
From: THROSBY, MARK; GEUIJEN, CECILIA A.W.; DE KRUIF, CORNELIS A.
To: CRUCELL HOLLAND B.V.
Reel/Frame 021807/0427 →
Priority Claims (2)
EP 06124231 · Nov 16, 2006 · regional
EP 07103584 · Mar 6, 2007 · regional
Continuity (2)
Provisional Application 60811477 · Jun 6, 2006
Related Publication 20090104204A1 · Apr 23, 2009